BioSpace News Archive

Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), has entered into an agreement with Novotech Health Holdings (“Novotech”), a leading full-service contract research organization (“CRO”) in Asia-Pacific, for its upcoming Phase 1 study in Australia of its SBI-100 drug candidate for the treatment of glaucoma.

Sera Prognostics Inc. today announced that the company will present at the upcoming virtual 42nd Annual Cowen Health Care Conference and the virtual Oppenheimer 32nd Annual Healthcare Conference.

Forwardly, Inc. (OTCMKT: FORW) announced today that its partially owned subsidiary and partner, Ligand Innovation Global (“Ligand”), has received acknowledgment of receipt of its application for Emergency Use Authorization of the LifeAir Portable Ventilator, also known as the VitaCaeli Portable Ventilator, by the United States Food and Drug Administration (“FDA”).

Aruvant Sciences announced management will participate in multiple gene therapy conferences taking place in March.

Dante Labs today announced the expansion of its Dante 30X Whole Genome Sequencing Test with personalized interpretation leveraging Dante’s proprietary Extensa Software Platform.

GT Biopharma, Inc. announced that Dr. Greg Berk, President of R&D, Chief Medical Officer and Interim CEO, will participate in a fireside chat in-person at the 34th Annual ROTH Conference on Tuesday March 15, 2022, at 8:30 AM PT.

Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced financial results for the year ended December 31, 2021.

Palatin Technologies, Inc. today announced that it will host a key opinion leader (KOL) webinar on the unmet medical need in treating patients with dry eye disease (DED) on Monday, March 7, 2022 at 10:30 am ET.

CytoImmune Therapeutics, a clinical-stage cell-therapy company developing a novel class of tumor-reactive engineered natural killer cell-based cancer immunotherapies, today announced that the executive management team will participate in the Cowen’s 42nd Annual Health Care Conference.

Innoviva, Inc. (NASDAQ: INVA) (the “Company” or “Innoviva”) today announced the pricing of $225 million aggregate principal amount of the Company’s 2.125% convertible senior notes due 2028 (the “Notes”).